CJC-1295, a modified form of GRF 1-29 NO DAC, is a peptide hormone that contains 29 amino acids. Since the 2000’s, the compound has been studied to explore the lipolytic properties, particularly the visceral fat elimination. The compound is able to conjugate with serum albumin, thereby increasing the half-life and therapeutic potential. CJC-1295 stimulates the pituitary gland, and promotes protein biosynthesis. Research suggests CJC-1295 might increase secretion of growth hormones and IGF-1 but not prolactin. The molecular weight and formula of the compound is 3367.979 and C152H252N44O42, respectively.

The modified GRF 1-29 is a modified version of the growth hormone releasing factor with Gln, Ala, Leu, and D-Ala substituted on position 8, 15, 27, and 2, respectively. The substitution is important in creating a more stable peptide and each substitution plays a key role. Substitution at position 27 prevents the oxidation of methionine, position 15 enhances the bioactivity of the peptide, and position 8 reduces asparagines rearrangement while position 2 prevents the DPP-IV cleavage process. CJC-1295 and CJC-1295 DAC are both analogs of the growth hormone releasing hormone; their mode of action is similar, however, the main difference between the two peptides is the half-life. Many scientists consider Mod GRF 1-29 to be more natural because it stimulates the HGH release in a pulsatile manner. One of the studies on CJC -1295 indicates that the peak shown by the hormone is preferable for the immediate increase in GH, however a combined therapy is mostly recommended because it can balance the release of the hormone while inhibiting somatostatin, thereby increasing GH per somatotrope.

CJC-1295 Chemical Profile

CAS: 863288-34-0
Formula: C152H252N44O42
Molecular weight: 3367.2
Peptide purity: > 99.0%
Chain:Tyr-d-ALA-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2